Please login to the form below

Not currently logged in
Email:
Password:

Depomed and Watson sign co-promotion deal

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including Puerto Rico.

Per the agreement, Depomed will book top-line revenue and Watson will receive a portion of the profits. Watson and Depomed plan to re-launch ProQuin XR in the US urology market by the end of this year.

Depomed retains manufacturing and distribution rights and Watson will be responsible for promotion to physicians in urology and long-term care.

Extended release versions of ciprofloxacin are also sold by Germany-based Bayer and Indian pharmaceutical company Ranbaxy.

According to a Market Research report, fluoroquinolone sales are expected to remain relatively constant to 2011. The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65 per cent (USD 3.3bn) of global sales.

25th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...